While activating RET mutations are associated with thyroid carcinomas and multiple endocrine neoplasias, there are no publicly available datasets that would allow us to correlate clinical outcome with the expression of Enigma and Cbl-c. The gene discussed is CBLC; the disease is thyroid gland carcinoma.